Tech takes VC so start-ups look to BIRAC as Indian 'messiah'
This article was originally published in Scrip
With venture capital funds (VCs) behaving almost like bankers when it comes to investing in Indian biotech, the government has emerged as the new "messiah" for start-ups in the sector, according to Dr P M Murali, president of the Association of Biotechnology Led Enterprises (ABLE) and managing director and CEO of Evolva Biotech.
You may also be interested in...
The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.